Glutathione is an important antioxidant in the brain that appears to be decreased, in conjunction with mitochondrial complex I activity, in Parkinson's disease patients. In postmortem analysis, measurement of glutathione levels and complex I activity can be delayed up to 20 h. We investigated if depletion of glutathione in the pre-weanling rat induces a reduction in complex I activity in brain mitochondria and the effect that postmortem delay has on glutathione levels and electron transport chain activities.
Introduction
Parkinson's disease is characterised by a selective decrease in dopamine in the striatum caused by a degeneration of dopaminergic neurones in the zona compacta of the substantia nigra [1, 2] . The primary cause of Parkinson's disease remains unknown, but several factors including oxidative stress and deficiencies in mitochondrial function have been associated with this debilitating disease [3] .
Evidence for oxidative stress occurring in Parkinson's disease has come from studies that show a decrease (up to 40%) in levels of the cellular antioxidant, glutathione (GSH) [4] [5] [6] [7] . GSH protects cells from oxidant damage [8, 9] and has been shown to reduce levels of reactive free radicals, including semiquinones and the hydroxyl radical. Furthermore, in view of the susceptibility of the mitochondrial electron transport chain (ETC) to oxidative stress, loss of GSH is associated, in some cell types, to impaired activity of one or more of the respiratory chain complexes [10, 11] .
With regards to Parkinson's disease, post mortem studies reveal a loss of mitochondrial function, in particular at the level of complex I [12,13] and this defect is associated with a loss of GSH. Since studies upon brain material from patients with incidental Lewy body disease (thought to be presymptomatic Parkinson's disease) reveal GSH deficiency in the absence of mitochondrial dysfunction [7] it has been proposed, in view of the susceptibility of the ETC to oxidative damage, loss of GSH may be an early and contributing event to the mitochondrial dysfunction noted in Parkinson's disease [14] [15] [16] [17] .
To date, metabolic studies upon Parkinson's disease material have largely been performed upon post mortem material which can have incurred delays of up to 20 hours. Thus, in view of the vulnerability of the ETC to oxidative stress and the GSH deficiency reported in Parkinson's disease, we considered the possibility that a preexisting GSH deficiency could elicit an artifactual oxidative inactivation of the ETC during a post mortem-delay. Therefore, in this study, we have depleted glutathione in rats and following postmortem delay, have investigated the maintenance of glutathione levels and the relationship to mitochondrial electron transport chain complex activities. The left hemisphere was homogenised (25% w/v in 15 mM o-phosphoric acid and following centrifugation (15,000 x g for 10 min) the supernatant was used for GSH analysis. The right hemisphere was homogenised (10% w/v) in isolation medium; 320 mM sucrose, 1 mM EDTA, 10 mM Tris (pH 7.4) and used for enzymatic analysis.
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Control and test samples were prepared together at 4 o C, to remove any effects of time on GSH status. All samples were stored at -70°C until assayed.
Mitochondrial enzyme assays. All assays were performed at 30°C. Prior to analysis, samples were freeze-thawed and gently shaken 3 times to ensure mitochondrial lysis was complete. Complex I activity was determined using a modification of the method of Ragan et al. [20] , and followed the oxidation of NADH at 340 nm using ubiquinone-1 as the electron acceptor. Complex II-III activity was determined as the antimycin A sensitive rate of cytochrome c (III) reduction at 550 nm, using the method of King [21] . Complex IV activity was determined by following the oxidation 
Determination of glututhione
GSH was assayed by high performance liquid chromatography and electrochemical detection [6] and is expressed as nmol/g wet weight.
Results

Glutathione levels decrease during postmortem delay
Inhibition of gamma-glutamylsynthetase in pre-weanling rats over an 11-day period by L-BSO decreased levels of glutathione by 53% (Fig.1A) . Following postmortem delay of 6, 12 and 24 h, glutathione levels decreased in the control rats by 27%, 37%
and 58%, respectively. In the L-BSO treated rats, during the postmortem delay of 6, 12 and 24 h, glutathione levels decreased in the control rats by 71%, 72% and 79%, respectively. However, the ratio of glutathione in L-BSO treated rats to control values remained between 50 to 60% at each time-point during the total post-mortem delay period (Fig. 1B ).
Glutathione depletion does not affect mitochondrial electron transport chain complex activities
Assay of mitochondrial respiratory chain complex I, II-III and IV activities revealed no changes in control or glutathione-depleted animals ( Tables 1, 2 and 3) . Similarly, the further reduction in glutathione during postmortem delay did not affect ETC activities. When these activities were expressed as ratios to citrate synthase activities no changes were observed indicating that when glutathione levels are decreased by up to 79% in the pre-weanling brain, there is no affect on ETC activities (Tables 1, 2 and 3).
Discussion
Administration of the gamma-glutamylcysteine synthetase inhibitor, L-BSO, over a period of 10 days decreased glutathione levels by 53% in brain homogenates of the pre-weanling rat ( Fig.1 ). This reduction of glutathione is consistent with that found in
other studies using L-BSO [10, 24] and is close to the reported 40% decrease in glutathione levels found in postmortem studies of Parkinson's disease patients [6] .
Even though glutathione reduction is found only in the substantia nigra in Parkinson's disease, the general glutathione reduction found in whole brain homogenates from the L-BSO treated preweanling rat provides a useful model in studying the effects of postmortem delay of glutathione levels and mitochondrial respiratory chain control complex activities.
Following a postmortem delay of 24 hours, total glutathione levels in both the control and L-BSO treated rats were decreased by 58 and 79%, respectively ( (Tables 1, 2 and 3) . This finding is in agreement with similar studies involving stereotaxic administration of L-BSO into adult rat brain [33] . While mitochondrial swelling, reductions in citrate synthase have been reported in non synaptic mitochondria prepared from rats that were pre-treated with L-BSO for 10 days [24, 10] , no effects on complex I activities were found in either homogenates or synaptic mitochondria.
In the case of complex IV, reduced activities (27%) were found in gradient-purified synaptic mitochondria but not in homogenates [10] , indicating that enrichment of brain mitochondrial fractions from glutathione depleted rats reveals complex IV defects. However, the consequences of such a complex IV deficiency on oxidative phosphorylation in brain mitochondria may be limited as complex IV activities must be inhibited by more than 60% in synaptic and non synaptic mitochondria before rates of respiration and ATP synthesis are severely affected [34] [35] [36] 37] .
During the postmortem delay period, glutathione levels were decreased, although this was found not to affect complex I, II-III or IV activities. These results do not support suggestions that the complex I defect observed in postmortem studies of the parkinsonian brain is associated with reduced levels of glutathione that may occur during the disease progression or the postmortem delay period. The results presented in this study differ from other studies that selectively depleted glutathione levels in cell culture models and observed decreases in complex I activities [36, 15, 16, 31, 14, 32] . In PC12 cells treated with L-BSO, glutathione levels were reduced by 90 % with a subsequent 50% decrease in complex I activity and an ablation of complex I energy thresholds [36, 38] . Reduced complex I activities are mainly specific to studies with neuronal cultures in which glutathione concentrations are almost totally ablated and may reflect a reliance on glycolytic metabolism in neurons and a reduction in mitochondrial metabolism, compared to the in vivo situation where mitochondria supply the majority of ATP in the neuron. One recent report suggested that glutathione depletion in adult mice using L-BSO induces a 40 % decrease in brain complex I activity [39] however, other studies have shown that L-BSO does not
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cross the blood brain barrier in adult mice or rats and has no affect on brain levels of glutathione [40] . In fact, only after acute and repeated intracerebroventricular infusion will L-BSO depelete glutathione levels [41] and even then, will not cause any nigrostriatal degeneration [42] . In a transgenic mouse model in which glutathione levels were reduced by 30-40%, complex I activity was found to be reduced by 26% in dopaminergic synaptosomes [31] however, the use of 2,6-dichlorophenolindophenol in the complex I assay may be problematic as 2,6-dichloroindophenol is capable of conjugating with mitochondrial thiol groups [43] and reduced glutathione [44] .
Glutathione depletion in the pre-weanling rat is a limited model as it may not necessarily reflect the effects of glutathione depletion in the aged or parkinsonian brain. The relative variations in levels of GSH in different brain regions are cortex>cerebellum>hippocampus>striatum>SN [45] [46] [47] , however, GSH profiles change through the lifespan, from high values during growth dropping to a maturation plateau and then decreasing 30% during aging [45] . Following preparation of synaptosomes from mouse brain, depletion of glutathione in vitro decreased ATP levels and viability of synaptosomes from aged mice but not from young mice [48] .
Nevertheless, following in vivo depletion of glutathione and a 24 h postmortem delay in which in glutathione levels are decreased by 79 %, approximately 2-fold more than in Parkinson's disease, there was no effect on complex I activity or complex II-III and IV activities.
These results suggest that the cause of complex I deficiency in Parkinson's disease is still unknown but is unlikely to be a postmortem artifact arising from a pre-existing glutathione deficiency state. Reduced complex I activities in mitochondria from
Parkin and PINK1 knockout animals [49, 50] as well as in leukocytes from patients with parkin mutations have been identified [51] , although interestingly, in parkin/DJ-1/PINK1 triple knockout mice no such deficiencies are present [52] . While such findings reveal possible causes of mitochondrial dysfunction in familial Parkinson's disease, the cause of complex I deficiency in the sporadic disease remains unknown. [21] King, T.S. Preparation of succinate cytochrome c reductase; and the cytochrome b-c1 particle; and reconstitution of succinate cytochrome c reductase.
Methods Enzymol. 10: 217-235; 1967.
[22] Wharton, D.C.; Tzagoloff, A. Cytochrome oxidase from beef heart mitochondria. Methods Enzymol. 10: 245-250; 1967.
[23] Shepherd, J.A.; Garland, P.B. Citrate synthase from rat liver. Methods Enzymol. 13: 11-9; 1969. A C C E P T E D M A N U S C R I P T 
ACCEPTED MANUSCRIPT
